Labarai

NEW DELHI, 22 ga Yuni (Xinhua) — Kamfanin samar da allurar rigakafi na Indiya mai suna Bharat Biotech Covaxin ya nuna ingancin kashi 77.8 cikin 100 a gwaje-gwajen mataki na uku, kamar yadda kafafen yada labarai da dama na cikin gida suka ruwaito a ranar Talata.

Wani rahoto ya ce "Covaxin na Bharat Biotech yana da tasiri kashi 77.8 cikin 100 wajen kare kai daga COVID-19, a cewar bayanai daga gwaje-gwajen mataki na uku da aka gudanar kan mahalarta 25,800 a fadin Indiya."

An bayyana ingancin maganin a ranar Talata bayan kwamitin kwararru kan harkokin magunguna na babban jami'in kula da magunguna na Indiya (DCGI) (SEC) ya gana tare da tattauna sakamakon.

Kamfanin harhada magunguna ya gabatar da bayanan gwaji na mataki na uku na allurar rigakafin ga DCGI a karshen mako.

Rahotanni sun ce ana sa ran kamfanin zai yi wani taro na "gabatar da bayanai" da hukumomin Hukumar Lafiya ta Duniya a ranar Laraba, domin tattauna ka'idojin mika bayanai da takardu da ake bukata na karshe.

Indiya ta fara yin allurar rigakafin cutar COVID-19 a ranar 16 ga Janairu ta hanyar ba da allurar rigakafi guda biyu da aka yi a Indiya, wato Covishield da Covaxin.

Cibiyar Nazarin Lafiya ta Indiya (SII) tana ƙera Covishield ta Jami'ar AstraZeneca-Oxford, yayin da Bharat Biotech ta haɗu da Majalisar Binciken Lafiya ta Indiya (ICMR) wajen ƙera Covaxin.

An kuma fara amfani da allurar rigakafin Sputnik V da aka yi a Rasha a kasar.